Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H32O3 |
| Molecular Weight | 344.4877 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)CCC(=O)C=C14
InChI
InChIKey=GZENKSODFLBBHQ-ILSZZQPISA-N
InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1
| Molecular Formula | C22H32O3 |
| Molecular Weight | 344.4877 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6336597 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
|||
| Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
|||
| Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
Disc. AE: Redness of eyelid, Swelling of eyelid... AEs leading to discontinuation/dose reduction: Redness of eyelid (1 patient) Sources: Swelling of eyelid (1 patient) Itching eyes (severe, 1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Redness of eyelid | 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
| Swelling of eyelid | 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
| Itching eyes | severe, 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma. | 2010-05 |
|
| [Effects of electroacupuncture of Sanyinjiao (SP 6) on genito-endocrine in patients with perimenopausal syndrome]. | 2007-08 |
|
| Behavioral and neurochemical effects on rat offspring after prenatal exposure to ethanol. | 2005-02-13 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:02:29 GMT 2025
by
admin
on
Wed Apr 02 07:02:29 GMT 2025
|
| Record UNII |
D2UFC189XF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
||
|
NDF-RT |
N0000175450
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
||
|
WHO-VATC |
QS01BA08
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
||
|
NDF-RT |
N0000175576
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
||
|
WHO-ATC |
S01BA08
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1662
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
DTXSID6045371
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
100000081994
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201173
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
D2UFC189XF
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
220-208-7
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
C47598
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
247839
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
C100283
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
2668-66-8
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
7086
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
SUB08701MIG
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
2039
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
m7135
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
D2UFC189XF
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
63278
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
29439
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | RxNorm | ||
|
MEDRYSONE
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY | |||
|
DB00253
Created by
admin on Wed Apr 02 07:02:29 GMT 2025 , Edited by admin on Wed Apr 02 07:02:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |